204 related articles for article (PubMed ID: 37545640)
1. Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study.
Crepaldi M; Maniero D; Massano A; Pavanato M; Barberio B; Savarino EV; Zingone F
World J Gastroenterol; 2023 Jul; 29(27):4334-4343. PubMed ID: 37545640
[TBL] [Abstract][Full Text] [Related]
2. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
Ranjan MK; Vuyyuru SK; Kante B; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
Int J Colorectal Dis; 2022 Aug; 37(8):1817-1826. PubMed ID: 35835862
[TBL] [Abstract][Full Text] [Related]
3. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
4. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.
Iborra M; Herreras J; Boscá-Watts MM; Cortés X; Trejo G; Cerrillo E; Hervás D; Mínguez M; Beltrán B; Nos P
Dig Dis Sci; 2019 Jun; 64(6):1612-1621. PubMed ID: 30604371
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
Mantzaris GJ; Sfakianakis M; Archavlis E; Petraki K; Christidou A; Karagiannidis A; Triadaphyllou G
Am J Gastroenterol; 2004 Jun; 99(6):1122-8. PubMed ID: 15180735
[TBL] [Abstract][Full Text] [Related]
6. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.
Cassinotti A; Actis GC; Duca P; Massari A; Colombo E; Gai E; Annese V; D'Albasio G; Manes G; Travis S; Porro GB; Ardizzone S
Am J Gastroenterol; 2009 Nov; 104(11):2760-7. PubMed ID: 19623172
[TBL] [Abstract][Full Text] [Related]
7. [Azathioprine in inflammatory bowel disease].
Leite S; Ribeiro JM; Lima SC; Barroso S; Cotter J
Acta Med Port; 2009; 22(1):33-40. PubMed ID: 19341591
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission.
Cassinotti A; Corona A; Duca P; Nebuloni M; Maconi G; Fociani P; Ardizzone S
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2293-2301.e1. PubMed ID: 34139332
[TBL] [Abstract][Full Text] [Related]
10. Azathioprine: state of the art in inflammatory bowel disease.
Sandborn WJ
Scand J Gastroenterol Suppl; 1998; 225():92-9. PubMed ID: 9515759
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease.
Lamers CB; Griffioen G; van Hogezand RA; Veenendaal RA
Scand J Gastroenterol Suppl; 1999; 230():111-5. PubMed ID: 10499471
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity.
Teich N; Mohl W; Bokemeyer B; Bündgens B; Büning J; Miehlke S; Hüppe D; Maaser C; Klugmann T; Kruis W; Siegmund B; Helwig U; Weismüller J; Drabik A; Stallmach A;
J Crohns Colitis; 2016 Jan; 10(1):61-8. PubMed ID: 26468141
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.
Fraser AG; Orchard TR; Jewell DP
Gut; 2002 Apr; 50(4):485-9. PubMed ID: 11889067
[TBL] [Abstract][Full Text] [Related]
14. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance.
Park MS; Kim DH; Kim DH; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
Dig Dis Sci; 2015 Jan; 60(1):195-204. PubMed ID: 25239495
[TBL] [Abstract][Full Text] [Related]
15. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.
Orth T; Peters M; Schlaak JF; Krummenauer F; Wanitschke R; Mayet WJ; Galle PR; Neurath MF
Am J Gastroenterol; 2000 May; 95(5):1201-7. PubMed ID: 10811328
[TBL] [Abstract][Full Text] [Related]
17. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy.
Campbell S; Ghosh S
Eur J Gastroenterol Hepatol; 2001 Nov; 13(11):1297-301. PubMed ID: 11692054
[TBL] [Abstract][Full Text] [Related]
18. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis.
Hibi T; Naganuma M; Kitahora T; Kinjyo F; Shimoyama T
J Gastroenterol; 2003; 38(8):740-6. PubMed ID: 14505127
[TBL] [Abstract][Full Text] [Related]
19. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
20. Bone density improves with disease remission in patients with inflammatory bowel disease.
Reffitt DM; Meenan J; Sanderson JD; Jugdaohsingh R; Powell JJ; Thompson RP
Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1267-73. PubMed ID: 14624148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
